258 related articles for article (PubMed ID: 33796147)
21. Ravulizumab: A Review in Generalised Myasthenia Gravis.
Kang C
Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
[TBL] [Abstract][Full Text] [Related]
22. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan.
Nishimura JI; Kawaguchi T; Ito S; Murai H; Shimono A; Matsuda T; Fukamizu Y; Akiyama H; Hayashi H; Nakano T; Maruyama S
Int J Hematol; 2023 Oct; 118(4):419-431. PubMed ID: 37515657
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
[TBL] [Abstract][Full Text] [Related]
24. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Howard JF; Bril V; Vu T; Karam C; Peric S; De Bleecker JL; Murai H; Meisel A; Beydoun SR; Pasnoor M; Guglietta A; Van Hoorick B; Steeland S; T'joen C; Utsugisawa K; Verschuuren J; Mantegazza R;
Front Neurol; 2023; 14():1284444. PubMed ID: 38318236
[TBL] [Abstract][Full Text] [Related]
26. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
Greenwood GT; Lynch Z
Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan.
Nakashima I; Nakahara J; Yokote H; Manabe Y; Okamura K; Hasegawa K; Fujihara K
Ther Adv Neurol Disord; 2023; 16():17562864231181177. PubMed ID: 37441104
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
[TBL] [Abstract][Full Text] [Related]
29. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF; Bresch S; Genge A; Hewamadduma C; Hinton J; Hussain Y; Juntas-Morales R; Kaminski HJ; Maniaol A; Mantegazza R; Masuda M; Sivakumar K; Śmiłowski M; Utsugisawa K; Vu T; Weiss MD; Zajda M; Boroojerdi B; Brock M; de la Borderie G; Duda PW; Lowcock R; Vanderkelen M; Leite MI;
Lancet Neurol; 2023 May; 22(5):395-406. PubMed ID: 37059508
[TBL] [Abstract][Full Text] [Related]
31. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
[TBL] [Abstract][Full Text] [Related]
32. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence.
Vu T; Wiendl H; Katsuno M; Reddel SW; Howard JF
Neuropsychiatr Dis Treat; 2023; 19():2639-2655. PubMed ID: 38059203
[TBL] [Abstract][Full Text] [Related]
33. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
[TBL] [Abstract][Full Text] [Related]
34. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis.
Monteleone JPR; Gao X; Kleijn HJ; Bellanti F; Pelto R
Front Neurol; 2021; 12():696385. PubMed ID: 34795626
[No Abstract] [Full Text] [Related]
35. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
Vu T; Meisel A; Mantegazza R; Annane D; Katsuno M; Aguzzi R; Enayetallah A; Beasley KN; Rampal N; Howard JF
NEJM Evid; 2022 May; 1(5):EVIDoa2100066. PubMed ID: 38319212
[TBL] [Abstract][Full Text] [Related]
36. Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
Katyal N; Govindarajan R; Goyal N; Muley S; Muppidi S
Front Neurol; 2024; 15():1378080. PubMed ID: 38919970
[TBL] [Abstract][Full Text] [Related]
37. Eculizumab for the treatment of myasthenia gravis.
Mantegazza R; Cavalcante P
Expert Opin Biol Ther; 2020 Sep; 20(9):991-998. PubMed ID: 32602752
[TBL] [Abstract][Full Text] [Related]
38. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.
Jia D; Zhang F; Li H; Shen Y; Jin Z; Shi FD; Zhang C
Aging Dis; 2024 Apr; 15(2):824-830. PubMed ID: 37450932
[TBL] [Abstract][Full Text] [Related]
39. Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report.
Vu T; Harvey B; Suresh N; Farias J; Gooch C
Case Rep Neurol; 2021; 13(1):65-72. PubMed ID: 33708096
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
Lien PW; Joshi M; Tice JA; Agboola F; Nikitin D; Withanawasam V; Jatoi S; Touchette DR
J Manag Care Spec Pharm; 2024 Jun; 30(6):517-527. PubMed ID: 38824625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
